MAP2K7 and colorectal cancer: A further study has shown that a combination of specific PI3K inhibitors (GDC-0941), rather than dual mTOR/PI3K inhibitors (NVP-BEZ235), with MEK inhibitors results in synergy in colorectal cancer cell lines [22].